Search Results

Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy

• Source: Phase II Trial of XL119 (Rebeccamycin Analogue) in Relapsed "Sensitive" Small Cell Lung Cancer

Record details

Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma

• Authors : National Cancer Institute (NCI)

• Source: A Pharmacokinetic-Guided Phase II Trial of the Rebeccamycin Analog NSC# 655649 in Pediatric Patients With Relapsed/Refractory Neuroblastoma

Record details

Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer

• Authors : National Cancer Institute (NCI)

• Source: A Phase II Study of Rebeccamycin Analog in Renal Cell CancerIbrahim D, Hussain M, LoRusso P, et al.: Rebeccamycin analog

Record details

Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer

• Source: A Phase I and Pharmacokinetic Study of Sequences of NSC 655649 (Rebeccamycin Analogue) and Cisplatin Without and With Granulocyte Colony-Stimulating Factor Support Every

Record details

Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

• Source: A Phase II Study of Rebeccamycin Analogue NSC 655649 in Patients With Metastatic Colorectal Cancer (IMT Codes 23988, 23989, 23993)

Record details

Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma

• Source: A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid TumorsLangevin AM, Bernstein M, Kuhn JG, Blaney SM, Ivy P, Sun J, Chen Z, Adamson

Record details

Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer

• Source: A Randomized Phase 2 Study of Rebeccamycin Analog in Advanced Breast Cancer

Record details

Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

• Source: A Phase I Study Of XL119 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphocytic Leukemia, Or Chronic Myeloid Leukemia In Blastic-Phase

Record details

Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors

• Source: A Phase I Study of XL119 (Rebeccamycin Analogue) in Combination With Oxaliplatin in Patients With Refractory Solid Tumors

Record details

Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer

• Authors : National Cancer Institute (NCI)

• Source: A Phase 2 Study of BMY-27557-14 (a Rebeccamycin Analog) in Patients With Ovarian Cancer

Record details